Effects of Ribosomal Protein L39-L on the Drug Resistance Mechanisms of Lung Cancer A549 Cells

  • Liu, Hong-Sheng (Intensive Care Unit of Affiliated Hospital of Jining Medical University) ;
  • Tan, Wen-Bin (Department of Pathogenic Biology, Jining Medical University) ;
  • Yang, Ning (Intensive Care Unit of Affiliated Hospital of Jining Medical University) ;
  • Yang, Yuan-Yuan (Department of Pathogenic Biology, Jining Medical University) ;
  • Cheng, Peng (A Grand Key Laboratory of Health Department, Shandong Institute of Parasitic Diseases) ;
  • Liu, Li-Juan (A Grand Key Laboratory of Health Department, Shandong Institute of Parasitic Diseases) ;
  • Wang, Wei-Jie (Department of Pathogenic Biology, Key Laboratory of Modern Pathogenic Biology of Jiangsu Province, Nanjing Medical University) ;
  • Zhu, Chang-Liang (Department of Pathogenic Biology, Key Laboratory of Modern Pathogenic Biology of Jiangsu Province, Nanjing Medical University)
  • Published : 2014.04.01


Background: Cancer is a major threat to the public health whether in developed or in developing countries. As the most common primary malignant tumor, the morbidity and mortality rate of lung cancer continues to rise in recent ten years worldwide. Chemotherapy is one of the main methods in the treatment of lung cancer, but this is hampered by chemotherapy drug resistance, especially MDR. As a component of the 60S large ribosomal subunit, ribosomal protein L39-L gene was reported to be expressed specifically in the human testis and human cancer samples of various tissue origins. Materials and Methods: Total RNA of cultured drug-resistant and susceptible A549 cells was isolated, and real time quantitative RT-PCR were used to indicate the transcribe difference between amycin resistant and susceptible strain of A549 cells. Viability assay were used to show the amycin resistance difference in RPL39-L transfected A549 cell line than control vector and null-transfected A549 cell line. Results: The ribosomal protein L39-L transcription level was 8.2 times higher in drug-resistant human lung cancer A549 cell line than in susceptible A549 cell line by quantitative RT-PCR analysis. The ribosomal protein L39-L transfected cells showed enhanced drug resistance compared to plasmid vector-transfected or null-transfected cells as determined by methyl tritiated thymidine (3H-TdR) incorporation. Conclusions and Implications for Practice: The ribosomal protein L39-L gene may have effects on the drug resistance mechanism of lung cancer A549 cells.


ribosomal protein L39-L;drug resistance mechanism;lung cancer;A549 cells


  1. Zhou YT, Li K, Tianh (2013). Effects of vinorelbine on cisplatin resistance reversal in human lung cancer A549/DDP cells. Asian Pac J Cancer Prev, 14, 635-9.
  2. Otsuka S, Tanaka M, Saito S, et al (1996). Molecular cloning of a cDNA encoding human ribosomal protein L39. Biochim Biophys Acta, 1308, 119-21.
  3. Maurice J (2013). Teaching old drugs new tricks raises hopes of new treatment for lung cancer. Lancet Respir Med, 1, 677.
  4. Nadano D, Notsu T, Matsuda T, et al (2002). A human gene encoding a protein homologous to ribosomal protein L39 is normally expressed in the testis and derepressed in multiple cancer cells. Biochim Biophys Acta, 1577, 430-6.
  5. Onn A, Bar J, Herbst RS (2014). Angiogenesis inhibition and lung-cancer therapy. Lancet Oncol, 15, 124-5.
  6. Pendharkar D, Ausekar BV, Gupta S (2013). Molecular Biology of Lung Cancer-A Review. Indian J Surg Oncol, 4, 120-4.
  7. Ridge CA, mcerlean AM, Ginsberg MS (2013). Epidemiology of Lung Cancer. Semin Intervent Radiol, 30, 93-8.
  8. Saha K, Basuthakur S, Jash D, Maji A (2013). Lung cancer presenting as visual impairment. South Asian J Cancer, 2, 86.
  9. Shrivastava SR, Shrivastava PS, Ramasamy J (2013). Lung cancer: Knowledge application gap. South Asian J Cancer, 2, 18.
  10. Tan W, Sun L, Zhang D, et al (2007). Cloning and overexpression of ribosomal protein L39 gene from deltamethrin-resistant Culex pipiens pallens. Exp Parasitol, 115, 369-78.
  11. Tardon A (2014). Genetic polymorphisms and lung cancer risk. Med Clin (Barc). [Epub ahead of print]
  12. Villanueva MT (2014). Lung cancer: Whack a gli hedgehog. Nat Rev Clin Oncol. [Epub ahead of print]
  13. Xu JL, Wang ZW, Hu LM, et al (2012). Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population. Asian Pac J Cancer Prev, 13, 2157-62.
  14. Chen SY, Hu SS, Dong Q, et al (2013). Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo. Asian Pac J Cancer Prev, 14, 6135-40.
  15. Brewer TF, Choi HW, Seas C, et al (2011). Self-reported risks for multiple-drug resistance among new tuberculosis cases: implications for drug susceptibility screening and treatment. PLoS One, 6, 25861.
  16. Chauhan PS, Bhushan B, Singh LC, et al (2012). Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy. Exp Mol Pathol, 92, 44-9.
  17. Chen Q, Wu N, Xie M, et al (2012). A novel asymmetric-loop molecular beacon-based two-phase hybridization assay for accurate and high-throughput detection of multiple drug resistance-conferring point mutations in Mycobacterium tuberculosis. Med Sci Monit, 18, HY5-8.
  18. Colijn C, Cohen T, Ganesh A, et al (2011). Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS One, 6, 18327.
  19. Edrington TS, Bischoff KM, Loneragan GH, et al (2014). Evaluation of feeding distiller's grains, containing virginiamycin, on antimicrobial susceptibilities in fecal isolates of Enterococcus and E. coli and prevalence of resistance genes in cattle. J Anim Sci. [Epub ahead of print]
  20. Hu MD, Xu JC, Fan Y, et al (2012). Hypoxia-inducible factor 1 promoter-induced JAB1 overexpression enhances chemotherapeutic sensitivity oflung cancer cell line A549 in an anoxic environment. Asian Pac J Cancer Prev, 13, 2115-20.
  21. Lin A, Mcnally J, Wool IG (1984). The primary structure of rat liver ribosomal protein L39. J Biol Chem, 259, 487-90.
  22. Baguley BC (2010). Multiple drug resistance mechanisms in cancer. Mol Biotechnol, 46, 308-16.

Cited by

  1. Drug Resistance Effects of Ribosomal Protein L24 Overexpression in Hepatocellular Carcinoma HepG2 Cells vol.15, pp.22, 2014,
  2. Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer vol.142, pp.10, 2016,
  3. pp.07394462, 2018,